Edition:
United States

People: AfroCentric Investment Corporation Ltd (ACTJ.J)

ACTJ.J on Johannesburg Stock Exchange

633.00ZAc
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
633.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
87,406
52-wk High
695.00
52-wk Low
475.00

Saunders, Brenton 

Mr. Brenton L. Saunders is a Chairman of the Board, President, Chief Executive Officer of the Company. He was President, Chief Executive Officer, Director of Allergan Plc. Mr. Saunders has served as a member of our Board of Directors and as Chief Executive Officer and President since July 2014. He was previously Chief Executive Officer and President of Forest beginning October 2013 and a member of the Board of Directors of Forest beginning 2011. Mr. Saunders served as Chief Executive Officer and as a Board Member of Bausch + Lomb Incorporated from March 2010 until August 2013, and as a senior executive with Schering-Plough from 2003 to 2010, most recently as President of Global Consumer Health Care. He also served as Head of Integration for both Schering-Plough’s merger with Merck & Co. and for Schering-Plough’s $16 billion acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. Prior to that, he was Chief Risk Officer at Coventry Health Care between 1998 and 1999 and a co-founder of the Health Care Compliance Association in 1995. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. In addition to the Bausch + Lomb Board of Directors, he served on the Board of Directors of ElectroCore LLC. He is also the former Chairman of the New York chapter of the American Heart Association. He is currently a member of the Board of Trustees of the University of Pittsburgh, The Business Council and PhRMA. The Board of Directors concluded that, based on Mr. Saunders’ leadership experience as Chief Executive Officer of two global healthcare companies and deep pharmaceutical experience, Mr. Saunders provides deep management and operational experience, as well as invaluable senior compliance experience and broad regulatory expertise, and therefore should serve as on the Board of Directors

Basic Compensation

Total Annual Compensation, USD 21,250,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 315,549
Fiscal Year Total, USD 21,565,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --